血液系统恶性肿瘤中的MUC1
MUC1 in hematological malignancies.
作者信息
Stroopinsky Dina, Kufe Donald, Avigan David
机构信息
a Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA ;
b Dana Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
出版信息
Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27.
Mucin1 (MUC1) is a transmembrane oncogenic protein that plays a central role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and c-Abl, which are of importance in the pathogenesis of various hematological malignancies. In myeloid leukemia, MUC1 has been shown to have an essential role in leukemia stem-cell function, the induction of reactive oxygen species (ROS), and the promotion of terminal myeloid differentiation. As such, MUC1 is an attractive therapeutic target in hematologic malignancies. Targeting MUC1 has been shown to be an effective approach for inducing cell death in tumor in in vivo and in vitro models. Furthermore, MUC1 inhibition is synergistic with other therapeutic agents in the treatment of hematologic disorders. This review will explore the role of MUC1 in hematological malignancies, and strategies for targeting this oncoprotein.
粘蛋白1（MUC1）是一种跨膜致癌蛋白，在恶性转化和疾病进展中起核心作用，包括细胞增殖、存活、自我更新和转移侵袭。MUC1已被证明可与多种效应分子相互作用，如β-连环蛋白、受体酪氨酸激酶和c-Abl，这些在各种血液系统恶性肿瘤的发病机制中具有重要意义。在髓系白血病中，MUC1已被证明在白血病干细胞功能、活性氧（ROS）的诱导以及终末髓系分化的促进中起重要作用。因此，MUC1是血液系统恶性肿瘤中一个有吸引力的治疗靶点。在体内和体外模型中，靶向MUC1已被证明是诱导肿瘤细胞死亡的有效方法。此外，MUC1抑制在血液系统疾病的治疗中与其他治疗药物具有协同作用。本综述将探讨MUC1在血液系统恶性肿瘤中的作用以及靶向这种癌蛋白的策略。
Zotero 插件